SCHEMBL6082860

SCHEMBL6082860

CC(C)=C(C)c1ccc(O[SiH](C)C)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.35
HPGD P15428 2/20 0.35
RAB9A P51151 1/20 0.35
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
HSD17B10 Q99714 3/20 0.33
TSHR P16473 2/20 0.33
MAPK1 P28482 2/20 0.33
USP2 O75604 1/20 0.33
ALOX15 P16050 1/20 0.33
ESR1 P03372 2/20 0.32
KDM4E B2RXH2 1/20 0.32
ALDH1A1 P00352 1/20 0.32
LMNA P02545 1/20 0.32
ADORA3 P0DMS8 1/20 0.32
CYP2C19 P33261 1/20 0.32
ADRA1A P35348 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HIF1A Q16665 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4454897 0.72 MEN1 (0.50) MAPTHPGDRAB9ACA1CA2
SCHEMBL18911076 0.70 NQO1 (0.61) MAPTHPGDRAB9ATSHRKDM4E
SCHEMBL12585158 0.69 ACHE (0.50) MAPTCA1CA2TSHRALDH1A1
SCHEMBL18905424 0.68 L3MBTL1 (0.42) MAPTESR1ALDH1A1LMNANPSR1
SCHEMBL5422997 0.67 LMNA (0.42) MAPTHPGDCA1CA2TSHR
SCHEMBL21295142 0.67 NFE2L2 (0.41) RAB9ACA1CA2CYP2C19L3MBTL1
SCHEMBL3146571 0.67 TDP1 (0.52) MAPTHPGDRAB9ATSHRMAPK1
SCHEMBL8744643 0.66 ESR1 (0.67) MAPTHPGDRAB9ACA1CA2
SCHEMBL2354326 0.66 CA4 (0.48) CA1CA2TSHRALDH1A1LMNA
SCHEMBL2768215 0.66 ALDH1A1 (0.50) MAPTHPGDRAB9AMAPK1ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7132432-B2 Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) BRISTOL-MYERS SQUIBB COMPANY (US) 2006-11-07 US disclosed
US-20040254231-A1 Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) BRISTOL-MYERS SQUIBB COMPANY 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254231-A1 Hydantoin derivatives as inhibitors of tumor necrosis factor-alpha converting enzyme (TACE) ADAM17, ADAMTS1, MMP3 MAPT 3750/4885HPGD 227/4885RAB9A 1588/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.